NVO - Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions | Benzinga
Eli Lilly and Co. (NYSE:LLY) enjoyed meteoric success with its weight loss drugs Mounjaro and Zepbound — the latter already recording stellar sales only three months after launch in December.
Recent data showed that, for the first time since launch, Zepbound filled more U.S. prescriptions in a single week than rival Novo Nordisk‘s (NYSE:NVO) Wegovy.
Whether or not this becomes a trend remains to be seen in the coming weeks, but it illustrated the power of Eli Lilly’s product portfolio.
And its weight loss drugs weren’t even the company’s fastest-growing treatments in terms of sales. Sales of its cancer drug Verzenio, according to full-year results, grew 56% year-on-year in 2023 to record $3.8 billion in sales.
Also Read: US Prescriptions Race For Weight Loss Drugs – Eli Lilly’s Zepbound Overtakes Novo Nordisk’s Wegovy